Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
PaperCitations, authors & open-access status
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 392 citations, 2021 year and green oa status.
392
Citations
2021
Year
green
OA Status